首页 > 市场调查报告书 > 製药

DDS

市场调查报告书

商品编码

1957054

日本静脉输液市场规模、份额、趋势和预测：按类型、营养成分和地区划分，2026-2034年

Japan Intravenous Solution Market Size, Share, Trends and Forecast by Type, Nutrients, and Region, 2026-2034

出版日期: 2026年02月01日 | 出版商:

IMARC | 英文 141 Pages | 商品交期: 5-7个工作天内

价格

简介目录

2025年日本静脉输液市值为9.6476亿美元，预计2034年将达到14.1428亿美元。预计2026年至2034年，该市场将以4.34%的复合年增长率成长。

受人口快速老化和需要营养干预的慢性病患者增多的推动，日本静脉输液市场正经历显着扩张。先进的医疗基础设施、政府扶持政策以及肠外製剂技术的创新，持续推动市场在各个临床应用领域的成长。

要点和见解：

按类型划分：预计到 2025 年，部分肠外营养将以 64% 的市占率主导市场。这是因为部分肠外营养广泛应用于需要同时进行口服或经肠营养以维持充足营养摄取的患者。
营养成分组成：到2025年，碳水化合物将以32%的市占率占据主导地位。这是因为碳水化合物在肠外营养製剂中作为主要能源来源发挥至关重要的作用，并广泛应用于需要肠外营养支持的各类患者。
区域细分：到2025年，关东地区将占据35%的市场份额，成为最大的细分市场。这主要是由于该地区集中了许多大型医院、医疗机构和製药公司，推动了对先进静脉输液的需求。
主要企业：日本静脉输液市场竞争激烈，本土老牌製药业者竞相从全球医疗保健公司手中夺取市场份额。市场参与企业正致力于配方创新、品质提升和策略联盟，以巩固其市场地位。

日本静脉输液市场受人口结构变化的驱动，该国老年人口比例位居世界前列，需要特殊营养护理的老年人比例极高。 2025年5月，大冢製药株式会社与ICU Medical公司完成合资企业成立，旨在加强静脉输液製剂的生产和创新，打造全球最大的静脉输液治疗生产网络之一。医疗保健系统日益重视综合病患管理，推动了对先进肠外营养解决方案的需求，以应对复杂的病理状况。製剂研发技术的进步拓展了治疗应用范围，引入了多腔输液袋和客製化营养组合，从而提高了治疗效果和患者预后。此外，日本强大的製药产业在胺基酸製剂、脂肪乳剂、维生素和矿物质製剂等领域不断创新，建构了满足多样化临床需求的产品系列。家庭肠外营养计画的日益普及，将市场范围扩展到医院之外，而支持性的报销政策也使患者更容易获得必要的静脉输液治疗。

日本静脉输液市场趋势：

先进的多腔袋配方

日本製药公司正在研发先进的多腔输液袋系统，将多种营养成分整合于同一输液袋中，并在给药前保持其稳定性和无菌性。 2024年9月，大冢製药株式会社的「Kidparen核准」获得上市许可。本产品是一种三腔全静脉营养，将胺基酸、葡萄糖、电解质和维生素整合于同一输液袋中，适用于慢性肾臟病病患者。这标誌着日本国内在先进肠外营养系统领域取得了显着进展。这些创新产品将胺基酸、葡萄糖、电解质、脂质和维生素整合于便利的即用输液袋中，缩短了配製时间并降低了污染风险。这种综合性单袋解决方案的研发进展有助于简化临床工作流程，并提高医疗机构的用药安全性。

扩大家庭肠外营养服务

在日本静脉输液（IVF）市场，居家IVF计画正日益普及，使慢性疾病患者能够在医院外接受营养治疗。 2025年，Air Water公司开设了东日本医疗中心，并扩大了包括家庭营养帮浦（HPN帮浦）在内的居家IVF设备的生产。这将满足日益增长的需求，并有助于提高居家照护患者的生活品质。医疗机构正在开发病患教育计画和支援系统，以促进安全的居家输液。这一趋势既能满足患者对更高生活品质的需求，又能减轻医疗机构的负担，并降低相关成本。

个人化营养处方

随着对个人化患者照护的日益重视，针对特定代谢需求和疾病状态的客製化肠外营养方案的研发正在不断推进。日本2024年发布的《重症监护营养管理指南》强调，应根据患者的临床状况和代谢需求调整肠外营养的给药时间和剂量，这标誌着日本全国范围内重症监护领域正朝着精准营养治疗的方向发展。医疗机构正在实施评估通讯协定，以便根据患者的病情、实验室检查结果和治疗目标进行精准的营养输注。这种个人化趋势有助于提高治疗效果，并最大限度地减少标准化治疗方案带来的併发症。

2026-2034年市场展望：

受人口结构因素、医疗基础设施投资和治疗方法创新等因素的支撑，日本静脉输液市场在预测期内呈现良好的成长前景。老年医疗保健服务、慢性病管理计画和专业营养支援的持续扩展将维持市场需求。预计该市场在2025年的营收将达到9.6476亿美元，并在2026年至2034年间以4.34%的复合年增长率增长，到2034年达到14.1428亿美元。

本报告解答的主要问题

1. 日本静脉输液市场规模有多大？

2. 日本静脉输液市场的预期成长率是多少？

3. 在日本，哪种类型的静脉输液市占率最大？

4. 市场成长的主要驱动因素是什么？

5. 日本静脉输液市场面临的主要挑战是什么？

Japan's intravenous solution market is experiencing significant expansion driven by the nation's rapidly aging population and rising prevalence of chronic diseases requiring nutritional intervention. The advanced healthcare infrastructure, coupled with supportive government policies and technological innovations in parenteral formulations, continues to fuel market growth across diverse clinical applications.

KEY TAKEAWAYS AND INSIGHTS:

By Type: Partial parenteral nutrition dominates the market with a share of 64% in 2025 , driven by its widespread application in patients requiring supplemental nutritional support alongside oral or enteral feeding to maintain adequate nutrient intake.
By Nutrients: Carbohydrates lead the market with a share of 32% in 2025 , owing to their essential role as primary energy sources in parenteral nutrition formulations and widespread utilization across diverse patient populations requiring intravenous nutritional support.
By Region: Kanto Region represents the largest segment with a market share of 35% in 2025 , attributed to its concentration of leading hospitals, healthcare facilities, and pharmaceutical companies driving demand for advanced intravenous solutions (IV).
Key Players: The Japan intravenous solution market exhibits a competitive landscape with established domestic pharmaceutical manufacturers competing alongside global healthcare corporations. Market participants focus on formulation innovations, quality enhancements, and strategic collaborations to strengthen their market positioning.

Japan's intravenous solution market is propelled by the nation's demographic transformation, characterized by one of the world's highest proportions of elderly citizens requiring specialized nutritional care. In May 2025, Otsuka Pharmaceutical Factory and ICU Medical completed the establishment of a joint venture aimed at bolstering IV solutions manufacturing and innovation, creating one of the largest global infusion therapy production networks. The healthcare system's emphasis on comprehensive patient management drives demand for advanced parenteral nutrition solutions addressing complex medical conditions. Technological advancements in formulation development have expanded treatment applications, introducing multi-chamber bags and customized nutrient combinations that enhance therapeutic efficacy and patient outcomes. Furthermore, Japan's robust pharmaceutical industry continues to innovate in areas including amino acid solutions, lipid emulsions, and vitamin-mineral preparations, creating diverse product portfolios catering to varied clinical requirements. The growing adoption of home parenteral nutrition programs is extending market reach beyond hospital settings, while supportive reimbursement policies facilitate patient access to essential intravenous therapies.

JAPAN INTRAVENOUS SOLUTION MARKET TRENDS:

Advanced Multi-Chamber Bag Formulations

Japanese pharmaceutical manufacturers are developing sophisticated multi-chamber bag systems that combine multiple nutritional components while maintaining stability and sterility until administration. In September 2024, Otsuka Pharmaceutical Factory obtained marketing approval for "KIDPAREN Injection," a three-chamber total parenteral nutrition solution that integrates amino acids, glucose, electrolytes, and vitamins in a single bag for patients with chronic kidney disease, illustrating local industry progress in advanced IV nutritional systems. These innovations integrate amino acids, glucose, electrolytes, lipids, and vitamins in convenient ready-to-use formats, reducing preparation time and contamination risks. The advancement toward comprehensive single-bag solutions streamlines clinical workflows and improves medication safety in healthcare settings.

Expansion of Home Parenteral Nutrition Services

The Japan intravenous solution market is witnessing growing adoption of home-based parenteral nutrition programs enabling patients with chronic conditions to receive nutritional therapy outside hospital environments. In 2025, Air-Water expanded home infusion equipment production, including HPN pumps, by opening the East Japan Medical Center, addressing growing demand and enhancing quality of life for home care patients. Healthcare providers are developing patient education initiatives and support systems facilitating safe home administration. This trend addresses patient preferences for improved quality of life while reducing healthcare facility burdens and associated costs.

Personalized Nutritional Formulations

Increasing emphasis on individualized patient care is driving development of customized parenteral nutrition solutions tailored to specific metabolic requirements and disease states. Japan's 2024 Critical Care Nutrition Guideline emphasizes tailoring parenteral nutrition timing and dosing to patients' clinical conditions and metabolic needs, signaling a nationwide shift toward precise nutrient therapy in critical care. Healthcare institutions are implementing assessment protocols enabling precise nutrient dosing based on patient conditions, laboratory values, and therapeutic goals. This personalization trend enhances treatment effectiveness and minimizes complications associated with standardized approaches.

MARKET OUTLOOK 2026-2034:

The Japan intravenous solution market demonstrates favorable growth prospects throughout the forecast period, supported by demographic factors, healthcare infrastructure investments, and therapeutic innovations. Continued expansion of geriatric care services, chronic disease management programs, and specialized nutritional support will sustain market demand. The market generated a revenue of USD 964.76 Million in 2025 and is projected to reach a revenue of USD 1,414.28 Million by 2034, growing at a compound annual growth rate of 4.34% from 2026-2034.

JAPAN INTRAVENOUS SOLUTION MARKET REPORT SEGMENTATION:

Type Insights :

Partial Parenteral Nutrition
Total Parenteral Nutrition

The partial parenteral nutrition dominates with a market share of 64% of the total Japan intravenous solution market in 2025.

Partial parenteral nutrition represents the largest type of segment in Japan's intravenous solution market, providing supplemental nutritional support to patients who can receive some nutrition through oral or enteral routes but require additional intravenous nutrients to meet their metabolic requirements. According to a 2024 report, Japanese hospitals have increasingly strengthened multidisciplinary Nutrition Support Teams (NSTs) to enhance parenteral nutrition practice, with clinical data showing NST-led interventions significantly improved implementation of recommended nutrition therapies, reflecting stronger institutional focus on appropriate nutrition support. This approach is widely utilized across hospital settings for patients recovering from surgery, experiencing temporary gastrointestinal dysfunction, or requiring enhanced nutritional intake during illness recovery periods.

The segment's dominance reflects clinical preferences for maintaining gastrointestinal function whenever possible while ensuring adequate nutrient delivery. Japanese healthcare protocols emphasize early enteral feeding combined with parenteral supplementation, driving demand for partial parenteral nutrition solutions. Manufacturers continue developing specialized formulations addressing specific clinical scenarios including post-operative care, oncology support, and geriatric nutrition, expanding the segment's application scope across diverse patient populations.

Nutrients Insights :

Carbohydrates
Salts and Electrolytes
Minerals
Vitamins
Amino Acids

The carbohydrates leads with a share of 32% of the total Japan intravenous solution market in 2025.

Carbohydrates constitute the leading nutrient segment in Japan's intravenous solution market, serving as the primary energy source in parenteral nutrition formulations. Glucose-based solutions provide essential caloric support for patients unable to maintain adequate oral intake, supporting metabolic functions and tissue preservation during periods of nutritional compromise. The widespread requirement for energy provision across virtually all parenteral nutrition applications ensures consistent demand for carbohydrate solutions.

Japanese pharmaceutical manufacturers offer diverse carbohydrate formulations with varying concentrations and compositions tailored to specific clinical requirements. The segment benefits from established clinical protocols integrating glucose administration into standard parenteral nutrition regimens across medical specialties. Ongoing research focuses on optimizing carbohydrate delivery rates and combinations with other nutrients to enhance metabolic outcomes and minimize complications associated with intravenous glucose administration.

Regional Insights:

Kanto Region
Kansai/Kinki Region
Central/Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region

The Kanto Region exhibits a clear dominance with a 35% share of the total Japan intravenous solution market in 2025.

The Kanto Region dominates Japan's intravenous solution market with the largest share, anchored by Tokyo's concentration of leading university hospitals, specialized medical centers, and pharmaceutical headquarters. The region's advanced healthcare infrastructure and high population density generate substantial demand for parenteral nutrition solutions across acute care and chronic disease management applications.

Additionally, Kanto's robust research ecosystem drives innovation in intravenous therapies, with numerous clinical trials and pilot programs evaluating novel formulations and multi-chamber bag systems. Collaboration between hospitals, biotech startups, and established pharmaceutical companies accelerates product development, ensuring rapid adoption of advanced IV solutions to meet the evolving nutritional needs of diverse patient populations.

MARKET DYNAMICS:

GROWTH DRIVERS:

Why is the Japan Intravenous Solution Market Growing ?

Rapidly Aging Population Requiring Nutritional Support

Japan possesses one of the world's most aged populations, with elderly citizens representing an expanding proportion of the total population. As of September 2025, an estimated 36.19 million Japanese citizens, nearly 29.4 % of the population, were aged 65 or older, the highest proportion recorded and highlighting Japan's status as the most aged society globally. This demographic transformation significantly influences healthcare demand, as older individuals frequently experience conditions affecting nutritional intake including swallowing difficulties, gastrointestinal disorders, and chronic diseases requiring medical intervention. The growing geriatric population creates sustained demand for parenteral nutrition solutions supporting patients unable to meet nutritional requirements through conventional feeding methods. Healthcare providers increasingly recognize the importance of adequate nutrition in elderly patient outcomes, driving adoption of intravenous solutions across hospitals, long-term care facilities, and home care settings.

Rising Prevalence of Chronic Diseases and Malnutrition

The increasing burden of chronic diseases including cancer, gastrointestinal disorders, and metabolic conditions drives demand for specialized nutritional interventions in Japan. According to reports, Japan reported 316,900 ulcerative colitis and 95,700 Crohn's cases, a 40 % rise over eight years, driving increased demand for comprehensive nutritional support, including parenteral nutrition. Patients with conditions affecting nutrient absorption or requiring intensive medical treatments often develop malnutrition necessitating parenteral support. Cancer patients undergoing chemotherapy or radiation therapy frequently require intravenous nutrition to maintain strength and support immune function during treatment periods. Similarly, patients with inflammatory bowel disease, short bowel syndrome, and other gastrointestinal conditions depend on parenteral nutrition for survival and quality of life maintenance, creating consistent market demand across clinical specialties.

Technological Advancements in Parenteral Formulations

Continuous innovation in parenteral nutrition technology expands market opportunities through improved product safety, efficacy, and convenience. Japanese pharmaceutical manufacturers develop advanced multi-chamber bag systems combining multiple nutritional components with extended stability profiles, enhancing clinical utility and reducing preparation requirements. Novel lipid emulsions incorporating beneficial fatty acid profiles improve patient tolerance and metabolic outcomes. Additionally, specialized formulations addressing specific disease states and patient populations broaden therapeutic applications. These technological advancements increase healthcare provider confidence in parenteral nutrition therapies, driving adoption across diverse clinical settings and patient populations.

MARKET RESTRAINTS:

What Challenges the Japan Intravenous Solution Market is Facing?

Complications Associated with Parenteral Nutrition Administration

Intravenous nutrition administration carries inherent risks including catheter-related infections, metabolic complications, and liver dysfunction that require careful patient monitoring and management. These potential complications necessitate specialized healthcare professional expertise and sophisticated monitoring protocols, limiting administration settings and increasing overall treatment costs. Concerns regarding long-term parenteral nutrition complications influence clinical decision-making toward alternative feeding methods when feasible.

High Treatment Costs and Reimbursement Pressures

Parenteral nutrition therapies involve substantial costs encompassing specialized formulations, administration equipment, professional monitoring, and potential complication management. Healthcare budget constraints and reimbursement system pressures create challenges for widespread therapy adoption, particularly for long-term treatments. Cost considerations influence clinical decisions regarding parenteral versus enteral nutrition approaches and treatment duration, potentially limiting market expansion in certain patient segments.

Shortage of Specialized Healthcare Professionals

Effective parenteral nutrition management requires healthcare professionals with specialized training in nutritional assessment, formulation prescription, and complication monitoring. Japan's healthcare workforce faces demographic challenges reflecting broader population trends, creating potential shortages of qualified personnel for specialized nutrition support services. Limited availability of trained nutrition support teams may constrain service expansion, particularly in regions with fewer major medical centers.

COMPETITIVE LANDSCAPE:

The Japan intravenous solution market exhibits a moderately consolidated competitive structure characterized by established domestic pharmaceutical manufacturers alongside global healthcare corporations. Market participants compete through product innovation, quality assurance, manufacturing capabilities, and distribution network strength. Domestic companies leverage understanding of local regulatory requirements and healthcare system dynamics, while international players contribute global research expertise and comprehensive product portfolios. Strategic activities including product launches, formulation improvements, and manufacturing investments characterize competitive dynamics. Manufacturers increasingly emphasize comprehensive nutritional solution portfolios addressing diverse patient needs, specialty formulations for specific clinical applications, and customer support services differentiating their market positioning.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the Japan intravenous solution market?

2. What is the projected growth rate of the Japan intravenous solution market?

3. Which type held the largest Japan intravenous solution market share?

4. What are the key factors driving market growth?

5. What are the major challenges facing the Japan intravenous solution market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Intravenous Solution Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Intravenous Solution Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Intravenous Solution Market - Breakup by Type

6.1 Partial Parenteral Nutrition
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Total Parenteral Nutrition
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)

7 Japan Intravenous Solution Market - Breakup by Nutrients

7.1 Carbohydrates
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Salts and Electrolytes
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 Minerals
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)
7.4 Vitamins
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2020-2025)
- 7.4.3 Market Forecast (2026-2034)
7.5 Amino Acids
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2020-2025)
- 7.5.3 Market Forecast (2026-2034)

8 Japan Intravenous Solution Market - Breakup by Region

8.1 Kanto Region
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Breakup by Type
- 8.1.4 Market Breakup by Nutrients
- 8.1.5 Key Players
- 8.1.6 Market Forecast (2026-2034)
8.2 Kansai/Kinki Region
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Breakup by Type
- 8.2.4 Market Breakup by Nutrients
- 8.2.5 Key Players
- 8.2.6 Market Forecast (2026-2034)
8.3 Central/ Chubu Region
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Breakup by Type
- 8.3.4 Market Breakup by Nutrients
- 8.3.5 Key Players
- 8.3.6 Market Forecast (2026-2034)
8.4 Kyushu-Okinawa Region
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2020-2025)
- 8.4.3 Market Breakup by Type
- 8.4.4 Market Breakup by Nutrients
- 8.4.5 Key Players
- 8.4.6 Market Forecast (2026-2034)
8.5 Tohoku Region
- 8.5.1 Overview
- 8.5.2 Historical and Current Market Trends (2020-2025)
- 8.5.3 Market Breakup by Type
- 8.5.4 Market Breakup by Nutrients
- 8.5.5 Key Players
- 8.5.6 Market Forecast (2026-2034)
8.6 Chugoku Region
- 8.6.1 Overview
- 8.6.2 Historical and Current Market Trends (2020-2025)
- 8.6.3 Market Breakup by Type
- 8.6.4 Market Breakup by Nutrients
- 8.6.5 Key Players
- 8.6.6 Market Forecast (2026-2034)
8.7 Hokkaido Region
- 8.7.1 Overview
- 8.7.2 Historical and Current Market Trends (2020-2025)
- 8.7.3 Market Breakup by Type
- 8.7.4 Market Breakup by Nutrients
- 8.7.5 Key Players
- 8.7.6 Market Forecast (2026-2034)
8.8 Shikoku Region
- 8.8.1 Overview
- 8.8.2 Historical and Current Market Trends (2020-2025)
- 8.8.3 Market Breakup by Type
- 8.8.4 Market Breakup by Nutrients
- 8.8.5 Key Players
- 8.8.6 Market Forecast (2026-2034)

9 Japan Intravenous Solution Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Products Offered
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Products Offered
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Products Offered
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Products Offered
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Products Offered
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Intravenous Solution Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis

12 Appendix

02-2729-4219

+886-2-2729-4219

License/价格